BIO - Bio-Rad Laboratories, Inc.
| Previous Close | 327.50 |
| Open | 331.65 |
| Bid | 332.55 x 900 |
| Ask | 333.04 x 900 |
| Day's Range | 330.57 - 333.47 |
| 52 Week Range | 220.05 - 338.67 |
| Volume | 23,373 |
| Avg. Volume | 173,911 |
| Market Cap | 9.889B |
| Beta (3Y Monthly) | 1.40 |
| PE Ratio (TTM) | 11.08 |
| EPS (TTM) | 29.97 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 385.00 |
- American City Business Journals
The $200K Club: NetApp's median employee gets a pay boost to join the salary ranks of Google, Netflix and Facebook
NetApp Inc. this year paid its median employee just shy of $200,000 — a level that puts it on par with some of Silicon Valley's biggest companies and represents a 26 percent jump, year-over-year.
- Zacks
PRGO vs. BIO: Which Stock Is the Better Value Option?
PRGO vs. BIO: Which Stock Is the Better Value Option?
- Zacks
Bio-Rad (Bio) Q2 Earnings Beat Estimates, Margins Expand
We are upbeat about Bio-Rad's (BIO) year-over-year revenue growth within the Clinical Diagnostics segment in Q2.
Motley FoolBio-Rad Laboratories Inc (BIO) (BIO-B) Q2 2019 Earnings Call Transcript
BIO, BIO-B earnings call for the period ending June 30, 2019.
- Zacks
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings and Revenue Estimates
Bio-Rad (BIO) delivered earnings and revenue surprises of 12.95% and 1.66%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Bio-Rad Reports Second-Quarter 2019 Financial Results
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2019.
- Simply Wall St.
Do Insiders Own Shares In Biome Grow Inc. (CNSX:BIO)?
A look at the shareholders of Biome Grow Inc. (CNSX:BIO) can tell us which group is most powerful. Institutions often...
- Zacks
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Delaware District Court Grants Bio-Rad’s Motion for Permanent Injunction Against 10X Genomics
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, announces that today the Delaware District Court granted Bio-Rad’s motion for permanent injunction against 10X Genomics from making any sales of infringing products to new customers and granting Bio-Rad’s request for supplemental damages and pre- and post-judgement interest. Today’s decision follows the Court’s decision earlier this month affirming the unanimous finding of a jury that 10X Genomics willfully infringed three United States Patents owned by the University of Chicago and exclusively licensed to Bio-Rad Laboratories, Inc. On November 13, 2018, a Delaware jury found all three patents valid and infringed, that 10X’s infringement was willful, and that Plaintiffs were entitled to $23.9 million in damages.
- Business Wire
Bio-Rad to Report Second-Quarter 2019 Financial Results
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, will report financial results for the second quarter 2019 on Thursday, August 1, 2019, following the close of the market.
- Zacks
IVD Market Sustains Momentum: 3 Stocks in Focus
In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.
- Zacks
ABT or BIO: Which Stock Has Better Potential Right Now?
Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.
- American City Business Journals
Facebook churns out a per-employee profit of $635K per year. How that compares with Apple, Google, Cisco, Oracle, Salesforce and others
Facebook makes more profit per employee than any other tech company on the Fortune 500: A whopping $634,694 per year. Here's how that compares with other major tech employers like Google, Apple and Cisco.
- Zacks
Here's Why You Should Invest in CONMED (CNMD) Stock Now
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.
- Zacks
Luminex (LMNX) Presents ARIES MRSA Assay to FDA for Clearance
Luminex (LMNX) submits the ARIES MRSA assay to the FDA for clearance. The company's ARIES system will get a substantial boost once the FDA clearance is through.
- Moody's
Bio-Rad Laboratories, Inc. -- Moody's announces completion of a periodic review of ratings of Bio-Rad Laboratories, Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Bio-Rad Laboratories, Inc. New York, July 01, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Bio-Rad Laboratories, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- Business Wire
Moody’s Upgrades Bio-Rad to Baa2, Reflecting Recent Improvement in the Company’s Operating Performance
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that Moody’s Investors Service (“Moody’s”) upgraded the unsecured rating of Bio-Rad Laboratories, Inc. senior unsecured notes to Baa2 from Baa3. The upgrade also reflects the company’s consistently strong credit metrics. In explaining its rationale for the upgraded credit rating, Moody’s noted that Bio-Rad’s Baa2 rating is supported by the company’s conservative capital structure and strong credit metrics.
- Moody's
Bio-Rad Laboratories, Inc. -- Moody's upgrades Bio-Rad to Baa2, outlook is stable
Moody's Investors Service ("Moody's") upgraded the unsecured rating of Bio-Rad Laboratories, Inc. ("Bio-Rad") to Baa2 from Baa3. The upgrade reflects the recent improvement in Bio-Rad's operating performance, including solid profit margin expansion, and progress made in its multi-year ERP implementation. The upgrade also reflects the company's consistently strong credit metrics.
- Insider Monkey
Here’s What Hedge Funds Think About Bio-Rad Laboratories, Inc. (BIO)
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. Trends reversed 180 degrees during the first quarter amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
- Simply Wall St.
What Kind Of Shareholder Appears On The BIOTON S.A.'s (WSE:BIO) Shareholder Register?
The big shareholder groups in BIOTON S.A. (WSE:BIO) have power over the company. Institutions will often hold stock in...
- American City Business Journals
9 major Bay Area tech employers pay a typical worker more than $200K per year
Large Bay Area tech employers that pay a typical employee more than $200,000 per year include the typical suspects like Google parent Alphabet Inc., Facebook and Netflix. But several companies that are lesser-known outside Silicon Valley also pay top dollar for talent.
- Markit
See what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.
Bio Rad Laboratories Inc NYSE:BIOView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BIO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIO. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $298 million over the last one-month into ETFs that hold BIO are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks
Bio-Rad (BIO) Down 6.9% Since Last Earnings Report: Can It Rebound?
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
Bio-Rad to Participate in Goldman Sachs Annual Global Healthcare Conference on June 11
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Ilan Daskal, Executive Vice President and CFO, will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11, at 10:40 AM , at the Terranea Resort, Rancho Palos Verdes, California.
- Zacks
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
Bio-Rad (BIO) continues to witness high investor confidence on strength in the Life Sciences segment.
